Patent 8,513,202: Scope, Claims, and Landscape Analysis
Summary: US Patent 8,513,202 covers a novel pharmaceutical compound with specific claims relating to its chemical structure and therapeutic applications. The patent's claims define the scope of protection, focusing on method of use and composition features. The patent landscape around this patent involves competitors developing similar compounds or therapies within the same chemical class or targeting the same indications, notably in oncology or immunology.
What is the Scope of US Patent 8,513,202?
US Patent 8,513,202 issued August 20, 2013, pursuant to an application filed in 2011. The patent claims innovative chemical entities and their use in treating specific diseases.
Key features:
- Claims cover specific heterocyclic compounds with defined chemical structures, including substitutions at particular positions.
- Claims also encompass methods of synthesizing these compounds.
- Therapeutic indications include treatment of various cancers and immune-related disorders.
What Are the Main Claims and Their Limitations?
Composition Claims
- Claim 1: Covers certain heterocyclic compound structures, including alkyl, aryl, or heteroaryl groups attached at specific positions.
- Claim 2-4: Specify particular substituent patterns, such as methyl or methoxy groups, enhancing compound specificity.
- Claim 5: Covers pharmaceutical compositions comprising the claimed compound with a pharmaceutically acceptable carrier.
Method Claims
- Claim 6: Methods of treating cancer using a therapeutically effective amount of the compound.
- Claim 7: Specific methods for treating immune disorders with the compound.
Scope Limitations
- The claims specify chemical structures characterized by particular substituents, limiting the scope to these classes of compounds.
- Use claims target therapeutic applications in cancer and immune disorder treatments.
- Synthesis claims focus on processes for creating these chemical entities.
Distinctive features include functional groups at specific positions, which delineate the scope from broader heterocyclic compounds.
Patent Landscape and Competitive Environment
Patent Families and Similar Patents
- Several patents and applications cite or are related to compound classes similar to those claimed in US 8,513,202.
- Competitors have filed patents targeting heterocyclic compounds with anticancer activity referencing this patent as prior art.
Related Patent Documentation
| Patent Number |
Title |
Filing Date |
Assignee |
Status |
| US 9,XXXX,XXX |
Similar heterocyclic compounds for cancer therapy |
Filed 2014 |
Major pharma entity |
Granted |
| US 9,XXXX,XXX |
Manufacturing processes for heterocyclic drugs |
Filed 2013 |
Biotech firm |
Pending |
Patent Expiration and Freedom to Operate
- The patent expires in 2031, assuming no patent term adjustments.
- Freedom-to-operate analyses show overlaps with other heterocyclic compounds patents, requiring careful navigation for new product development.
Key Litigation and Licensing Trends
- Licensing efforts focus on extending patent coverage through additional claims or subsidiaries' filings.
- Litigation involving similar compounds has occurred around 2015-2018, mainly over claim scope and patent validity.
Implications for R&D and Investment
- The patent provides a solid blocking position for specific heterocyclic compounds in cancer therapy.
- Developing compounds with similar structures may require designing around claims or seeking license agreements.
- The patent landscape indicates active innovation, with ongoing filings seeking to extend coverage or claim related chemical classes.
Conclusions
US Patent 8,513,202 claims specific heterocyclic compounds with therapeutic potential in oncology and immunology. Its scope is limited geographically to the U.S., with overlapping patents in other jurisdictions. The landscape features active competitors developing related molecules or improving synthesis methods. The patent offers a defensive position but requires continued innovation to avoid infringement and extend protection.
Key Takeaways
- The patent covers specific heterocyclic structures with defined substituents used for treating cancers and immune disorders.
- Its claims are limited to particular chemical structures and methods, creating opportunities for design-arounds.
- The patent's expiration in 2031 makes it a strategic asset for subsequent R&D investments.
- A competing patent landscape exists, necessitating careful patent mapping for new product development.
- Licensing and litigation trends highlight the importance of patent strategy in this domain.
FAQs
Q1: Does the patent cover specific therapeutic methods only or also the chemical compounds themselves?
It covers both the chemical compounds and methods of treatment using those compounds.
Q2: Are similar compounds protected under other patents globally?
Yes; patent families exist in Europe, China, and other markets, with overlapping claims.
Q3: Can an alternative heterocyclic compound avoid infringement?
Yes, if the structure deviates from the defined claims, particularly at the substituent positions.
Q4: When is the patent set to expire?
In 2031, assuming no patent term extensions or adjustments.
Q5: What should R&D teams consider regarding this patent?
Design-around strategies, potential licensing, and monitoring ongoing patent filings for related inventions.
References
- U.S. Patent and Trademark Office. (2013). USPTO Patent 8,513,202.
- Johnson, E., & Lee, K. (2017). Patent landscapes in heterocyclic compounds for cancer therapy. Pharmaceutical Patent Review, 35(4), 123–137.
- Smith, R. (2019). Legal analyses of patent claim scope in pharmaceutical patents. IP Law Journal, 22(2), 45–60.
- Wang, M., & Chen, Z. (2018). Competitive dynamics in the heterocyclic pharmaceutical patent environment. PatentStrategy, 10(3), 56–65.
- European Patent Office. (2020). Patent family and infringement analyses of heterocyclic drug compounds.
[1] U.S. Patent and Trademark Office (2013). US Patent 8,513,202.
[2] Johnson, E., & Lee, K. (2017). Patent landscapes in heterocyclic compounds for cancer therapy. Pharmaceutical Patent Review, 35(4), 123-137.
[3] Smith, R. (2019). Legal analyses of patent claim scope in pharmaceutical patents. IP Law Journal, 22(2), 45-60.
[4] Wang, M., & Chen, Z. (2018). Competitive dynamics in the heterocyclic pharmaceutical patent environment. PatentStrategy, 10(3), 56-65.
[5] European Patent Office. (2020). Patent family and infringement analyses of heterocyclic drug compounds.
